Original scientific paper

Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series

Nicoletta Bernardini ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Nevena Skroza orcid.org/0000-0003-4478-5404 ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Ilaria Proietti ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Alessandra Mambrin ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Anna Marchesiello ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Ersilia Tolino ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Veronica Balduzzi ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy
Concetta Potenza ; Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Italy

Abstract

Erythrodermic psoriasis (EP) is a very rare but extremely
severe subtype of chronic plaque psoriasis,
affecting 1.00-2.25% of patients with psoriasis (1).
Its pathogenesis still remains unknown, and current
therapeutic strategies frequently end in failure. In this
condition, the skin becomes diffusely red, tending to
purple, shiny, with marked desquamation and exudation.
Erythema and edema are widespread, covering
more than 90% of the body surface and can lead to
high risk of multi-organ failure and death (2) due to
fluid and protein loss.
Predominance of the Th2 immune response and
dysregulation of angiogenesis have been proposed
to be implicated in the pathogenesis of EP, although
this has not yet been fully elucidated (3).
Nevertheless, Th17 has been shown to be the
second-most predominant T-cell type after Th2 in EP
lesions (4,5).

Keywords

psoriasis, erythrodermic psoriasis, treatment, anti IL-17

Hrčak ID:

274680

URI

https://hrcak.srce.hr/274680

Publication date:

15.12.2021.

Visits: 984 *